GHRS icon

GH Research

14.31 USD
+0.00
0.00%
At close Feb 14, 4:00 PM EST
After hours
14.31
+0.00
0.00%
1 day
0.00%
5 days
2.80%
1 month
74.73%
3 months
59.53%
6 months
45.43%
Year to date
80.91%
1 year
78.88%
5 years
-25.66%
10 years
-25.66%
 

About: GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.

Employees: 49

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

7% more call options, than puts

Call options by funds: $29K | Put options by funds: $27K

0% more funds holding

Funds holding: 28 [Q2] → 28 (+0) [Q3]

0.38% less ownership

Funds ownership: 59.04% [Q2] → 58.66% (-0.38%) [Q3]

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

43% less capital invested

Capital invested by funds: $358M [Q2] → $204M (-$154M) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$14
2%
downside
Avg. target
$27
91%
upside
High target
$40
180%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
Cantor Fitzgerald
Charles Duncan
57% 1-year accuracy
46 / 81 met price target
2%downside
$14
Overweight
Initiated
13 Feb 2025
HC Wainwright & Co.
Patrick Trucchio
40% 1-year accuracy
70 / 173 met price target
180%upside
$40
Buy
Reiterated
27 Jan 2025
Canaccord Genuity
Sumant Kulkarni
26% 1-year accuracy
9 / 34 met price target
96%upside
$28
Buy
Maintained
18 Nov 2024

Financial journalist opinion

Based on 6 articles about GHRS published over the past 30 days

Positive
Zacks Investment Research
1 week ago
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
GH Research stock soars 55% in a week after the company meets the primary goal in a mid-stage depression study of its lead candidate, GH001.
GHRS Stock Rallies 55% in a Week: Here's What You Should Know
Neutral
GlobeNewsWire
1 week ago
GH Research Announces Pricing of $150 Million Public Offering
DUBLIN, Feb. 05, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of its previously announced underwritten public offering in the United States of 10,000,000 ordinary shares at a public offering price of $15.00 per share for total gross proceeds of approximately $150 million. All of the ordinary shares are being offered by GH Research PLC. The offering is expected to close on February 6, 2025, subject to customary closing conditions. In addition, GH Research PLC has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 ordinary shares at the public offering price, less underwriting discounts and commissions.
GH Research Announces Pricing of $150 Million Public Offering
Neutral
GlobeNewsWire
1 week ago
GH Research Announces Proposed Public Offering
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the commencement of an underwritten public offering in the United States of $150 million of ordinary shares. All of the ordinary shares are to be offered by GH Research PLC. In addition, GH Research PLC intends to grant the underwriters an option to purchase up to an additional $22.5 million of ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
GH Research Announces Proposed Public Offering
Positive
Benzinga
1 week ago
Why Is GH Research Stock Trading Higher On Monday?
On Monday, GH Research PLC GHRS said its Phase 2b trial with GH001, an inhalable bufotenin product candidate for treatment-resistant depression, met its primary endpoint.
Why Is GH Research Stock Trading Higher On Monday?
Neutral
GlobeNewsWire
1 week ago
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
DUBLIN, Feb. 03, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company, today reported the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase 2b clinical trial with GH001, an inhalable mebufotenin product candidate, in patients with treatment-resistant depression (TRD) (GH001-TRD-201). GH Research will host a conference call and live webcast today at 8.00 a.m. EST. To register for the event, please click here.
GH Research Announces Primary Endpoint Met in Phase 2b Trial with GH001 in TRD Demonstrating -15.5 Point Placebo-adjusted MADRS Reduction
Neutral
GlobeNewsWire
2 weeks ago
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it will host a conference call and live webcast on Monday, February 3, 2025, at 8.00 a.m. EST to provide an update on data from the randomized, double-blind, placebo-controlled Phase 2b trial of GH001 in treatment-resistant depression (TRD).
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
Neutral
GlobeNewsWire
1 month ago
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
DUBLIN, Jan. 10, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.
GH Research Announces Primary Endpoint Met in Two Phase 2a POC Trials with GH001 and Completion of All FDA Requests to Address IND Hold with No Findings of Respiratory Toxicity in Non-Rodents
Positive
Zacks Investment Research
2 months ago
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
The mean of analysts' price targets for GH Research (GHRS) points to a 225.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
Neutral
GlobeNewsWire
3 months ago
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
DUBLIN, Nov. 14, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2024, and provided updates on its business.
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
Positive
MarketBeat
3 months ago
3 Fast-Growing Stocks Analysts See Doubling in Price
Comparing and selecting stocks for investment may involve any number of increasingly complex strategies and approaches, but sometimes simpler is better: targeting a stock with significant upside potential at an opportune moment. Certainly, achieving this goal is easier said than done, and there is no guarantee that a company expected to make sizable gains will follow through on that promise.
3 Fast-Growing Stocks Analysts See Doubling in Price
Charts implemented using Lightweight Charts™